In utero hematopoietic stem cell transplantation (IUHSCTx) is a promising therapeutic approach for the treatment of a variety of congenital hematologic disorders. However, in the absence of a selective advantage for normal cells, clinical and experimental efforts at IUHSCTx have resulted in limited or no detectable engraftment, supporting the existence of major barriers to engraftment in the hematopoietically competitive recipient. The long-term objective of this project is to develop clinically applicable strategies to increase engraftment to therapeutic levels. Overcoming the engraftment barrier would allow increased clinical application of IUHSCTx with the potential for reduced morbidity, mortality, and cost, relative to currently available therapy.
The specific aims of this proposal are: 1. To optimize donor cell subpopulations for engraftment after in utero HSC transplantation. The requirements for homing, lodgement and engraftment to the fetal liver are poorly understood. Donor cell populations differ in their engraftment efficiency. Using novel strategies, specific donor cell populations will be compared for their early kinetics of engraftment, the relative repopulating ability of engrafted cells, and the competitive capacity after IUHSCTx of equivalent repopulating populations. This will provide insight into the relative ability of specific donor populations to engraft after IUHSCTx and into the relative importance of initial number of HSC engrafted, versus the competitive capacity of the donor population, for the achievement of high level engrafment. 2. To investigate the efficacy of immune based strategies to enhance engraftment prenatally, and to increase levels of chimerism postnatally.
This Specific Aim has three goals: 1) To identify and validate specific donor derived cell populations that can facilitate prenatal engraftment of enriched HSC without graft versus host disease (GVHD); 2) to investigate prenatal immunotherapeutic strategies to suppress GVHD and improve engraftment of non-enriched donor populations after IUHSCTx; and 3) to test the efficacy of immunotherapeutic approaches after birth to reduce or eliminate host hematopoiesis in the mixed chimeric recipient made tolerant by IUHSCTx. The studies in this proposal are designed to identify and test strategies to increase engraftment after IUHSCTx. This would allow application of this approach to a broad range of prenatally diagnosed genetic disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL064715-01A1
Application #
6333326
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Mishoe, Helena
Project Start
2001-06-15
Project End
2005-05-30
Budget Start
2001-06-15
Budget End
2002-05-30
Support Year
1
Fiscal Year
2001
Total Cost
$340,000
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Peranteau, William H; Hayashi, Satoshi; Abdulmalik, Osheiza et al. (2015) Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants. Blood 126:1245-54
Peranteau, William H; Heaton, Todd E; Gu, Yu-Chen et al. (2009) Haploidentical in utero hematopoietic cell transplantation improves phenotype and can induce tolerance for postnatal same-donor transplants in the canine leukocyte adhesion deficiency model. Biol Blood Marrow Transplant 15:293-305
Niiya, Masami; Endo, Masayuki; Shang, Dezhi et al. (2009) Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther 17:34-41
Laje, Pablo; Shang, Dezhi; Cao, Wenjing et al. (2009) Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 113:2172-80
Merianos, Demetri J; Tiblad, Eleonor; Santore, Matthew T et al. (2009) Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice. J Clin Invest 119:2590-600
Peranteau, William H; Endo, Masayuki; Adibe, Obinna O et al. (2007) Evidence for an immune barrier after in utero hematopoietic-cell transplantation. Blood 109:1331-3
Peranteau, William H; Endo, Masayuki; Adibe, Obinna O et al. (2006) CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood 108:4268-74
Ashizuka, Shuichi; Peranteau, William H; Hayashi, Satoshi et al. (2006) Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation. Exp Hematol 34:359-68
Shaaban, Aimen F; Kim, Heung Bae; Gaur, Lasya et al. (2006) Prenatal transplantation of cytokine-stimulated marrow improves early chimerism in a resistant strain combination but results in poor long-term engraftment. Exp Hematol 34:1278-87
Hayashi, Satoshi; Hsieh, Michael; Peranteau, William H et al. (2004) Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes. Exp Hematol 32:290-9

Showing the most recent 10 out of 15 publications